Search





Search





Markets
/
Stocks
/
nasdaq-qntm
/

Quantum BioPharma Ltd

QNTM

Add to Watchlist

6.595USD

+1.125+20.57%

Market hours （ET）Quotes delayed by 15 min

38.62MMarket Cap

LossP/E TTM



Quantum BioPharma Ltd

6.595

+1.125+20.57%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Quantum BioPharma Ltd

Currency: USD Updated: 2026-05-13

Key Insights

Quantum BioPharma Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 175 out of 383 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 40.25.In the medium term, the stock price is expected to trend up.Despite a strong stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Quantum BioPharma Ltd's Score

Industry at a Glance

Industry Ranking

175 / 383

Overall Ranking

311 / 4487

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Quantum BioPharma Ltd Highlights

StrengthsRisks

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Fairly Valued

The company’s latest PE is -0.73, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 568.64K shares, decreasing 53.02% quarter-over-quarter.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

40.250

Target Price

+695.45%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-13

The current financial score of Quantum BioPharma Ltd is 6.69, ranking 213 out of 383 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.69

Change



Financials

8.93

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.73

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Quantum BioPharma Ltd's Company Valuation

Currency: USD Updated: 2026-05-13

The current valuation score of Quantum BioPharma Ltd is 6.08, ranking 323 out of 383 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.73, which is -68.94% below the recent high of -0.23 and -308.32% above the recent low of -2.97.

Score

Industry at a Glance

Previous score

6.08

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 175/383

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-13

The current earnings forecast score of Quantum BioPharma Ltd is 8.00, ranking 161 out of 383 in the Biotechnology & Medical Research industry. The average price target is 40.25, with a high of 45.00 and a low of 35.50.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

40.250

Target Price

+695.45%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Quantum BioPharma Ltd

QNTM

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

Beigene Ltd

ONC

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-13

The current price momentum score of Quantum BioPharma Ltd is 5.20, ranking 327 out of 383 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 6.74 and the support level at 3.63, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.21

Change

-0.01

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.061

Buy

RSI(14)

63.108

Neutral

STOCH(KDJ)(9,3,3)

47.027

Neutral

ATR(14)

0.716

High Vlolatility

CCI(14)

61.551

Neutral

Williams %R

23.118

Buy

TRIX(12,20)

1.872

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

5.124

Buy

MA10

5.274

Buy

MA20

4.562

Buy

MA50

3.857

Buy

MA100

4.796

Buy

MA200

9.845

Sell

Institutional Confidence

Currency: USD Updated: 2026-05-13

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Malone Wealth Ventures LLC

375.75K

-64.12%

Saeed (Zeeshan)

233.21K

+96.96%

Durkacz (Anthony)

143.92K

+394.33%

Carroll (Donal)

114.31K

+26.43%

AdvisorShares Investments, LLC

96.25K

+158.48%

Lynch (Terrence)

51.42K

Jane Street Capital, L.L.C.

10.89K

Kotra (Lakshmi)

29.57K

Citadel Advisors LLC

15.86K

Risk Assessment

Currency: USD Updated: 2026-05-13

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Quantum BioPharma Ltd is 1.38, ranking 307 out of 383 in the Biotechnology & Medical Research industry. The company's beta value is 0.37. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.